Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with overall 7% growth for the year. Shares fell more than 10% as Merck paused ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...

Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

The ethics document said Mr. Kennedy would continue to collect fees for cases in which he referred clients to Wisner Baum, a law firm suing Merck over Gardasil, a vaccine that protects against the ...

Wisner Baum is representing a plaintiff in a trial against Merck and other lawsuits are ... in Wisner Baum's suits against Merck over its HPV vaccine, which is to prevent cervical cancer.